GLIAA Trial Results: Contrast-Enhanced MRI Remains the Gold Standard for Re-irradiation Planning in Recurrent Glioblastoma
The multicenter GLIAA trial demonstrated that FET-PET-guided target volume delineation for re-irradiation does not provide a progression-free survival benefit over standard contrast-enhanced T1-weighted MRI in patients with recurrent glioblastoma, solidifying MRI's role as the preferred clinical delineation method.